These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23570098)

  • 1. Treatment of mild anemia.
    Waltzman RJ
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-38-41. PubMed ID: 23570098
    [No Abstract]   [Full Text] [Related]  

  • 2. Erythropoietin: high profile, high scrutiny.
    Crawford J
    J Clin Oncol; 2007 Mar; 25(9):1021-3. PubMed ID: 17312331
    [No Abstract]   [Full Text] [Related]  

  • 3. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
    Steensma DP
    J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668
    [No Abstract]   [Full Text] [Related]  

  • 4. Erythropoietin-stimulating agents: new data yield new insights.
    Zitella L
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl Nurse Ed):36-8. PubMed ID: 18154208
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia.
    Vaupel P; Dunst J; Engert A; Fandrey J; Feyer P; Freund M; Jelkmann W
    Onkologie; 2005 Apr; 28(4):216-21. PubMed ID: 15840971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines for the use of recombinant human erythropoietin.
    Barosi G; Cazzola M; De Vincentiis A; Grossi A; Tura S
    Haematologica; 1994; 79(6):526-33. PubMed ID: 7896210
    [No Abstract]   [Full Text] [Related]  

  • 7. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy.
    Anand A; Anand A; Anand N
    Cancer; 1996 May; 77(9):1960-1. PubMed ID: 8646701
    [No Abstract]   [Full Text] [Related]  

  • 8. Cancer-related anemia and recombinant human erythropoietin--an updated overview.
    Bohlius J; Weingart O; Trelle S; Engert A
    Nat Clin Pract Oncol; 2006 Mar; 3(3):152-64. PubMed ID: 16520805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is anemia of cancer different from chemotherapy-induced anemia?
    Steensma DP
    J Clin Oncol; 2008 Mar; 26(7):1022-4. PubMed ID: 18227523
    [No Abstract]   [Full Text] [Related]  

  • 10. The clinical utility of epoetin in cancer patients: a matter of perspective.
    Barosi G; Marchetti M
    Haematologica; 2000 May; 85(5):449-50. PubMed ID: 10800156
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical application of recombinant erythropoietin in anemic cancer patients.
    Henry DH
    Hematol Oncol Clin North Am; 1994 Oct; 8(5):961-73. PubMed ID: 7852218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction. Improving the standard of care in the management of cancer-related anaemia: focus on darbepoetin alfa, a novel erythropoiesis-stimulating protein.
    Glaspy J
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):1-2. PubMed ID: 11308267
    [No Abstract]   [Full Text] [Related]  

  • 13. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia.
    Yang MC
    Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of a strategy to successfully convert an ambulatory infusion center from epoetin alfa to darbepoetin alfa.
    Longfield V; Gebhart B; Hayward L
    J Support Oncol; 2005; 3(6 Suppl 4):8-9. PubMed ID: 16355548
    [No Abstract]   [Full Text] [Related]  

  • 15. Strategies to optimize the use of erythropoietin and iron therapy in oncology patients.
    Ford PA; Mastoris J
    Transfusion; 2004 Dec; 44(12 Suppl):15S-25S. PubMed ID: 15585001
    [No Abstract]   [Full Text] [Related]  

  • 16. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR; Dunst J; Vaupel P
    Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of erythropoietin in the treatment of cancer-related anemia].
    Huang JX; Meng FJ
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):877-8. PubMed ID: 22335959
    [No Abstract]   [Full Text] [Related]  

  • 18. Epoetin alfa and darbepoetin alfa go head to head.
    Steensma DP; Loprinzi CL
    J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021
    [No Abstract]   [Full Text] [Related]  

  • 19. Erythropoietins should be used according to guidelines.
    Aapro MS; Birgegård G; Bokemeyer C; Cornes P; Foubert J; Gascon P; Glaspy J; Hellström-Lindberg E; Link H; Ludwig H; Osterborg A; Repetto L; Soubeyran P
    Lancet Oncol; 2008 May; 9(5):412-3. PubMed ID: 18452853
    [No Abstract]   [Full Text] [Related]  

  • 20. Utilizing quality of life as a factor in treatment choices for chemotherapy-induced anemia.
    Koopman W; Iakiri S
    J Support Oncol; 2005; 3(6 Suppl 4):20-1. PubMed ID: 16355554
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.